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Abstract
Background: Obese individuals who smoke have a 14 year reduction in life expectancy. Both obesity and smoking are
independantly associated with increased risk of malignancy. Natural killer cells (NK) are critical mediators of anti-tumour
immunity and are compromised in obese patients and smokers. We examined whether NK cell function was differentially
affected by cigarette smoke in obese and lean subjects.
Methodology and Principal Findings: Clinicaldataandbloodwerecollectedfrom40severelyobesesubjects(BMI.40 kg/m
2)
and 20 lean healthy subjects. NK cell levels and function were assessed using flow cytometry and cytotoxicity assays. The effect
of cigarette smoke on NK cell ability to kill K562 tumour cells was assessed in the presence or absence of the adipokines leptin
and adiponectin. NK cell levels were significantly decreased in obese subjects compared to lean controls (7.6 vs 16.6%,
p=0.0008). NK function was also significantly compromised in obese patients (30% +/2 13% vs 42% +/212%, p=0.04).
Cigarette smoke inhibited NK cell ability to kill tumour cell lines (p,0.0001). NK cells from obese subjects were even more
susceptible to the inhibitory effects of smoke compared to lean subjects (33% vs 28%, p=0.01). Cigarette smoke prevented NK
cell activation, as well as perforin and interferon-gamma secretion upon tumour challenge. Adiponectin but not leptin partially
reversed the effects of smoke on NK cell function in both obese (p=0.002) and lean controls (p=0.01).
Conclusions/Significance: Obese subjects have impaired NK cell activity that is more susceptible to the detrimental effects
of cigarette smoke compared to lean subjects. This may play a role in the increase of cancer and infection seen in this
population. Adiponectin is capable of restoring NK cell activity and may have therapeutic potential for immunity in obese
subjects and smokers.
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Introduction
Obesity and smoking, independently are important factors for ill
health. A recent meta-analysis has shown that obesity is associated
with 25–40% of certain malignancies [1], in particular oesopha-
geal adenocarcinoma, thyroid, renal and colon cancers, multiple
myeloma and leukaemia in both obese men and women. It has
been reported that this cancer risk is remediable by weight loss [2].
Smoking is the main cause of preventable morbidity and mortality
in the developed world [3]. Obese individuals who smoke have a
14 year reduction in life expectancy at the age of 40 [4]. A large
prospective study has shown that smoking coupled with obesity
contributes substantially to all-cause mortality, with 3.5 to 5-fold
risks for severely obese current smokers compared to normal
weight non-smokers [5]. Obese smokers also have an increased
risk of developing both Type 2 Diabetes [6] and cancer [5]. It is
likely that carcinogens contained in cigarette smoke can induce
malignancy directly [7,8]. How smoking and obesity might
interact to reduce life expectancy is not clear.
Additional mechanisms contribute to the increased cancer
risk associated with cigarette smoke [8]. Immune compromised
animals have an increased incidence of cancer [9]. The host
immune system plays a critical role in surveillance, detection and
elimination of aberrant cells. In particular, natural killer (NK) cells
are important innate immune effectors against malignancy,
viruses, parasites and bacteria [10,11]. NK cells have the capacity
to kill certain tumour cells without prior sensitization [11], control
tumour growth in vivo and prevent the dissemination of tumours
[12]. Previous studies have shown that anti-tumour cell activity of
NK cells is reduced in smokers compared to non-smokers [13]. In
mice, cigarette smoke is associated with increased lung tumour
burden specifically due to the effects of cigarette smoke on NK cell
dependent tumour immune surveillance [8]. In addition, smokers
have increased susceptibility to infections [14]. Combined, these
studies suggest smoking may weaken host immunity, enabling
tumour cells and pathogens to evade immune responses.
Obesity is associated with immune dysfunction and may be
an immune-compromised state itself [15,16,17]. In diabetic obese
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[18]. Furthermore, after infection, diet induced obese mice have
reduced NK cytotoxicity and higher mortality compared to lean
mice [19]. We have previously shown that obese subjects have
decreased circulating NK and cytotoxic T cell levels with altered
phenotypes [17]. The objective of this study was to examine NK
function in obese subjects compared to lean subjects and also to
assess the effects of cigarette smoke extract (CSE) on circulating
NK cell function in both groups. Given the proposed role for
the adipokines in modulating immune function, we investigated
whether leptin or adiponectin impacted on NK activity.
Materials and Methods
Subjects
Ethics Statement: The ethics committee at St. Vincent’s
University Hospital, Dublin granted approval for all aspects of
this study. All blood samples were obtained with informed written
consent.
Patients: 40 consecutive obese subjects who were referred to our
hospital-based weight management clinic were studied. Their
mean age was 42, range 18–60 years; mean BMI 51 kg/m
2, range
40–72; 14 males and 26 females. All obese patients were classified
as metabolically unhealthy, meaning they had high fasting glucose,
high blood pressure and/or high triglyceride/HDL cholesterol
ratios using cut-off points adapted from the International Diabetes
Federation worldwide consensus definition of the metabolic
syndrome, 2006. No obese subjects were on immune modulating
medication or clinical history known to affect the immune system.
20 lean healthy controls were also studied (mean age 35, range
23–54 years; mean BMI 24 kg/m
2, range 22–25; 7 males and 13
females). All subjects were non-smokers.
Preparation of Peripheral Blood Cell Suspensions
Fifteen mls of peripheral blood was collected in heparinized tubes
after an overnight fast. Blood samples were analyzed on the day
of collection. Peripheral blood mononuclear cells were prepared
by standard density gradient centrifugation over Lymphoprep
(Nycomed, Oslo, Norway) at 400 g for 25 min. Cells were washed
twice with HBSS supplemented with HEPES buffer solution
(Invitrogen Life Technologies, Paisley, UK) and antibiotics
(100 U/ml penicillin, 100 mg/ml streptomycin) and 5% FCS
(Invitrogen Life Technologies). Cell pellets were re-suspended in
1 ml of RPMI 1640 medium, and cell yields and viability were
assessed by ethidium bromide/acridine orange staining. The cell
suspension was adjusted to1610
6 cells/ml in RPMI 1640 medium.
Cell Surface Staining of Cells with Monoclonal Antibodies
for Flow Cytometric Analysis
Aliquots of 100 ml( 1 610
5) of cells were labeled with monoclonal
antibodies (mAbs) directed against cell surface markers classically
associated with cells of the immune system. For the identification/
detection of leukocytes, fluorescein (FITC)-labeled anti-CD45
mAb (clone: HI30) BD Biosciences, Oxford, UK) was included in
all tubes. For the identification of NK cells (CD56
+CD3
2) and
NKR
+T cells (CD56
+CD3
+), PE CD56 (B159) and PerCP-labeled
anti-CD3 (SK7) mAb were also included. The appropriate mAbs
(0.3 mg/ml final concentration) were added to cells, which were
incubated in the dark at 4uC for 30 min. Cells were then washed
twice with 1 ml of PBS-BSA-azide. Labeled cells were fixed in
0.5 ml of 1% paraformaldehyde (Sigma-Aldrich, Poole, UK).
Appropriate isotype-matched fluorescent-labeled nonspecific anti-
bodies were used to correct for any background staining.
To investigate the effects of CSE on NK cell surface markers,
NK cells were incubated for 4 hours with K562 tumour cells with
or without smoke extract. After incubation, NK cells were stained
with monoclonal antibodies for flow cytometric analysis with NK
cell surface inhibitory antigens (FITC-labeled anti-CD158a (HP-
3E4) and CD158b (CH-L), anti-NKB1 (DX9)), activatory marker
anti-CD69 (L78), cytotoxic granule markers anti-CD107a (1D4B)
and anti-CD107b (ABL-93) in addition to anti-CD56 (NK) and
anti-CD3 (T) staining. To detect intracellular cytokine production
by NK and T cells upon challenge with K562 tumour cells, after
the 4 hour incubation, cells were stained for flow cytometry as
before and then permeabilized with saponin before intracellular
mAb staining. 5 ml of PE labeled anti-IFN-c (B27), anti-TNF-a
(MAb11) and anti-IL-10 (JES3-9D7) were added to tubes in
addition to CD56 and CD3.
Flow Cytometric Analysis
Cells were analyzed using a FACSCalibur flow cytometer and
CellQuest Pro software (BD Biosciences). Lymphocytes were gated
(‘lymphogate’) by their density and granularity using forward
scatter and side scatter parameters, which contained .95% of
peripheral lymphocytes. Lymphocytes (CD45
+) were also gated
using side scatter and FITC parameters. All further analysis was
performed on CD45 cells only. While all CD45 cells are not
lymphocytes, the combination of using CD45+ staining and the
‘lymphogate’ based on size and granularity ensured .95% of cells
analysed were lymphocytes. Thirty thousand CD45
+ events were
acquired in each case. CD3 and CD56 staining levels above that of
appropriate isotype controls were analyzed within the CD45
+
population. Results were expressed as a percentage of CD45
+
lymphocytes. To assess reproducibility of flow cytometric analysis
of peripheral lymphocytes, peripheral blood was collected again
from four individuals after 8 and 24 weeks. No changes in the
relative proportions of lymphoid populations were detected.
Cigarette Smoke Extract (CSE)
A system for generating cigarette smoke was developed based
upon a validated pump system [20], as per modifications of
Cawood et al [21]. Smoke from four cigarettes was pumped
through 30 ml RPMI culture medium. Ten puffs were pumped for
each cigarette, each puff contributing 35 ml of smoke, every
30 sec, resulting in approximately 75% of the cigarette being
consumed, and the 350 ml of smoke extract was generated per
cigarette. Each milliliter of CSE contains 0.133 (4/30) cigarette’s
worth of smoke-derived constituents. The resultant CSE was
sterilized by filtering through a 0.2-mm filter, pH adjusted to 7.4,
and then stored at 220 C. The cigarettes used were Marlboro
Reds, Class A, rated as tar 10 mg, nicotine 0.8 mg, and carbon
monoxide 10 mg. Bernhard’s validated volumetric calculations
[20] are based on the assumption that a human generates 350 ml
smoke with each cigarette and has a blood volume of 6 liters.
If that person smokes 20 cigarettes per day, then each 300 ml
(6000/20) of blood contains the equivalent of one cigarette.
Therefore, each milliliter of blood contains 0.0033 (1/300)
cigarette’s worth of smoke-derived constituents. By this calcula-
tion, CSE can be considered to contain 40 times (0.133/0.0033)
the amount of smoke-derived constituents than would be expected
to be contained in the blood of a smoker who smokes 20 cigarettes
per day. A 2.5% (1/40) solution of CSE would equate to 20
cigarettes per day. To measure a dose response, we used between
1.25% CSE and 5% CSE, which equates to 10–40 cigarettes per
day, respectively. All other experiments were carried out using
2.5% CSE equating to 20 cigarettes per day.
NK Cells in Obesity
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NK cells were isolated from PBMCs of all patients by positive
selection using anti-CD56 mAb-coated magnetic beads (Miltenyi
Biotec, Gladbach Bergische, Germany), according to the manu-
facturer’s instructions. NK cell and K562 cell numbers and
viability were measured by ethidium bromide/acridine orange
staining. Following isolation, K562 target cells were labeled with
carboxy fluorescein succinimidyl ester (CFSE) and then added to
the NK cell populations at various effector/target ratios (1:1, 10:1,
20:1). Cell co-cultures were incubated at 37uC for 4 h, in the
absence or presence of CSE. Killing of CFSE-labeled K562 cells
was measured by staining with 7-aminoactinomycin D (7-AAD)
immediately after incubation and by immediate analysis by flow
cytometry (as per manufactucters instructions for the flow
cytometry-based Total Cytotoxicity & Apoptosis Detection Kit,
Immunochemistry, Bloomington, MN). To investigate the effects
of adipokines on NK cytotoxicity, adiponectin (Recombinant
Human Adiponectin/Acrp30 RnD Systems, 2.5 mg/ml) or leptin
(Recombinant Human Leptin, RnD Systems,10 ng/ml), were
added to wells with and without CSE. Cytotoxicity assays used
various effector: target ratios as mentioned to validate the assays,
however due to reduced numbers of NK cells in some patients,
each ratio was not possible for each person. Therefore an effector:
target ratio of 10:1 was chosen for each patient for comparison and
it is this ratio that is discussed in the results.
Statistical Analysis
Differences between groups were assessed using the Mann-
Whitney U test for nonparametric data, ANOVA for 3 or more
groups, or a Student’s paired t test where appropriate. Statistical
significance was accepted as P,0.05.
Results
Cell Yields and Viability
There were no significant differences in PBMC yields and
viability between lean controls and obese patients. The mean
mononuclear cell yield obtained from 15 mls of blood was
16.2610
6 cells in lean controls and 15.0610
6 cells in obese
subjects. Cell viability in all cases exceeded 90%.
NK Cell Level and Function in Obesity
Obese subjects had significantly fewer circulating NK (CD56
+
CD3
2) cells (mean 7.6% of all lymphocytes; range 2.2–19.0,
n=40) than lean healthy controls (mean, 16.6%; range, 7.6–28.6%,
n=20, p=0.0008; Figure 1A). Furthermore, NK cell cytotoxic
function, measured by their ability to kill K562 tumour cells in vitro,
was significantly reduced in obese subjects (mean 30% tumour cells
lysed, range 9–51%, n=40) compared to lean controls (mean, 42%
tumour cells lysed; range 21–57%, n=10, p=0.04; Figure 1B). The
same ratio of effector (NK) cells from lean and obese subjects to
target (K562) cells was used in each experiment (10:1). Therefore
thelevelsofcirculatingNKcellsshouldnotaffectcytotoxicfunction.
Effect of Cigarette Smoke Extract (CSE) on NK Cell
Cytotoxicity
NK cell function was measured by their ability to kill K562
tumour cells in the presence or absence of CSE. NK cells from all
patients specifically lysed K562 target cells in vitro. As a positive
control, the NK cell activator, IL-2 significantly enhanced NK cell
cytotoxicity by 45% (32% vs 46% targets killed, p=0.0001;
Figure 2A). CSE significantly reduced NK cell ability to lyse target
cells by 29% (n=50 [all subjects], mean 32% vs 21%, p,0.0001;
Figure 2A). CSE equivalent to 20 cigarettes per day was used in all
experiments. CSE did not affect NK cell or target cell viability
during the experiment (data not shown). CSE acted in a dose-
dependent manner. The effect of CSE equivalent to 10 cigarettes
per day did not significantly differ from the effects of the
equivalent of 20 cigarettes per day on NK cell function. However,
CSE equivalent to 40 cigarettes per day was more detrimental to
NK cell cytotoxic function that that of 10 or 20 cigarettes per day
(p=0.01; Figure 2B).
The Effect of CSE on Obese and Lean Subjects
The effects of CSE on cytotoxicity of NK cells from obese and
lean subjects were examined. NK cells from obese subjects were
more sensitive to the effects of CSE than those from lean controls.
Cigarette smoke reduced NK cells ability to lyse tumour cells in
both obese (30% vs 20% targets killed, n=40, p,0.0001) and lean
subjects (42% vs 30% targets killed, n=10, p=0.004; Figure 3A).
However the percentage decrease in NK cell cytotoxic ability was
significantly greater in obese (33% decreased function/1.65 fold
reduction) than in lean controls (28% decreased function/1.3 fold
reduction, p=0.01; Figure 3B).
The Effect of Adipokines on NK Cell Function
The possibility that adipokines might influence the differential
effects of CSE on NK cells from obese and lean subjects was
examined. Specifically, the influence of adipokines adiponectin
and leptin on NK cell function was investigated. Leptin inhibited
Figure 1. Natural killer cell level and function in obesity. A. Circulating natural killer cells were significantly reduced in obese subjects (n=40)
compared to lean healthy controls (n=20), *p=0.0008. B. NK cytotoxic function was also significantly lower in obese subjects (n=40) compared to
lean subject (n=10). *p=0.04 with Mann Whitney U test.
doi:10.1371/journal.pone.0008660.g001
NK Cells in Obesity
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leptinvs.38%,n=10,p=0.04,Figure 3C). Leptindidnotalter NK
cell function in obese subjects (30% vs. 31%, n=40, Figure 3C).
However, adiponectin significantly enhanced NK cell ability to kill
target cells by 11%, compared to when adiponectin was absent in
lean controls (42% vs 47% target cells killed, n=10, p=0.01) but
not in obese subjects (30% vs. 24%, p=0.7, Figure 3C). While the
effects of adipokines on NK cell function in obesity was not
significant, the trend was that adipokines had opposing effects on
NK cell function between lean and obese subjects (Figure 3C).
The Effect of Adipokines on CSE Mediated NK Cell
Cytotocicity
The potential of adiponectin and leptin to reverse the harmful
effects of CSE on NK cells was investigated. In the presence of
adiponectin, CSE inhibition on NK cell cytotoxicity was
significantly improved in both obese subjects (26% killed in
presence of adiponectin and CSE compared to 20% killed with
CSE alone, p=0.002) and lean subjects (35% vs 30%, p=0.01;
Figure 4 A & B). Leptin did not affect NK cytotoxicity in the
presence of CSE in either obese or lean subjects.
Figure 2. The effects of CSE on NK cytotoxic function. A. NK cell cytotoxicity was significantly enhanced in the presence of NK activatory
cytokine IL-2 (n=40, ***p=0.0001). CSE significantly reduced NK cell ability to lyse target cells (n=40, ***p,0.0001 using Students paired t test). CSE
equivalent to 20 cigarettes per day was used in all experiments. Error bars represent standard error of the mean. B. CSE acted in a dose dependent
manner. CSE equivalent to 40 cigarettes per day was more detrimental to NK cell cytotoxic function than CSE equivalent to 10 or 20 cigarettes per day
(n=5, correlation of number of cigarettes versus NK cytotoxicity: R
2=0.847).
doi:10.1371/journal.pone.0008660.g002
Figure 3. The effects of CSE on NK cytotoxic function in obese and lean subjects. A. Cigarette smoke reduced NK cell ability to lyse tumour
cells in both obese (***p,0.0001; n=40) and lean subjects (**p=0.004; n=10). B. The percentage decrease in NK cell cytotoxicity was significantly
greater in obese subjects (33% reduced cytotoxicity) compared to lean controls (25% reduced cytotoxicity, *p=0.01). C. Adiponectin significantly
enhanced NK cell ability to kill target cells in lean controls, compared to when adiponectin was absent (42% vs 47% target cells killed, n=10,
**p=0.01). Adiponectin did not significantly affect NK cell function in obese subjects (30% vs 24%, n=40, p=0.7). Leptin inhibited NK cytoxicity in
lean subjects (n=10, p=*0.04) but in not obese subjects (n=40). Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0008660.g003
NK Cells in Obesity
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Cytokine Production
To investigate potential mechanisms underlying the effects of
CSE and adipokines on NK cell function, we measured 1) levels of
NK cell inhibitory (CD158a, CD158b and NKB1) cell surface
receptors, 2) up-regulation of CD107a, CD107b and CD69 and 3)
production of intracellular cytokines by NK cells in the presence or
absence of CSE basally or after K562 tumour challenge. When NK
cells were not challenged with tumour cells, CSE had no effect on
expression of NK cell surface receptors, perforin production,
activation status or cytokine production by NK cells. When NK
cells were stimulated with tumour cells, CSE significantly inhibited
NK cell ability to lyse tumour cells but CSE did not effect the
expression of CD158a, CD158b and NKB1. However CSE
significantly inhibited the activation and cytotoxic granule release
by NK cells. CD107a and CD107b mark the mobilization of the
lysosome-associated membrane proteins LAMP-1 and LAMP-2
found within cytotoxic granules in response to stimulation and
thus identify NK cell cytotoxic action [22], while human NK cells
express CD69 when stimulated and this activation antigen
represents a trigger in the cytolytic machinery of NK cells [23].
CSE inhibited the expression of activation marker CD69 by 30%
(20% vs. 14% of NK cells, n=14, p=0.006; Figure 5A and B) and
the expression of CD107a and CD107b by 19% (22% vs. 18%,
n=14, p=0.02; Figure 5A and B). While CSE caused a decrease of
intracellular interferon gamma (IFN-c) production and increase of
IL-10 production by NK cells in all cases, the effects were not
significant (IFN-c: 10.4% vs. 5.6%, n=5, p=0.09, IL-10: 1.7% vs
11.5%, n=5, p=0.1; Figure 5C) upon tumour challenge. However
adiponectin significantly enhanced production of IFN-c compared
to when smoke was present and restored IL-10 production towards
normal but this was not significant (IFN-c: 5.6% vs. 8.5%, n=5,
p=0.006, IL-10: 11.5% vs. 2.6% n=5, p=0.2; Figure 5C).
Discussion
The now established strong association between obesity and
cancer [1], and the profound effects of smoking on obese subjects
prompted this study [5]. Obese smokers aged 40 have a 14year
reduction in life expectancy compared to lean non-smokers [4].
Our findings show a marked reduction in the numbers and
function of NK cells in obese individuals. We also show increased
susceptibility of NK cells from obese subjects to the harmful effects
of cigarette smoke. These findings may partly explain the dismal
outcome for the obese smoker.
Figure 4. The effects of adipokines on NK cells in the presence of CSE. A. CSE significantly inhibited NK cell cytotoxic function. Adiponectin,
but not leptin could partially restore NK cell function to normal in both obese and lean subjects (adiponectin + smoke vs smoke alone, obese:
**p=0.002, lean: *p=0.01). Graphs represent the mean of obese (n=40) and lean subjects (n=10). B. Representative histograms of NK cell cytoxicity
of one obese subject. Tumour cells were stained with green membrane stain CFSE to distinguish target cells from effector cells. After 4 hours, viability
stain 7-AAD was added to measure the proportion of target cells lysed. CFSE
+ tumour cells were gated and the histograms represent the proportion
of dead cells (7-AAD
+). Percentages illustrate the mean fluorescent intensity (MFI) of 7-AAD.
doi:10.1371/journal.pone.0008660.g004
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viral infection. They act through detection and killing of cancerous
and infected cells [10] and also by producing cytokines including
IFN-c, which recruit the adaptive immune system [24,25]. We
have recently shown a reduction in the number of NK cells in
obese individuals [17]. This current study shows NK cells to
be markedly reduced, complimenting our previous finding of
decreased NK cell numbers in obesity. These findings are similar
to those in obese rats, which have reduced NK cell cytotoxicity
which is restored upon weight loss [26]. However, one previous
human study did not find any significant difference in spontaneous
NK cell cytotoxicity in obese subjects compared to lean controls
[27]. Dovio et al, however investigated NK cell activity in patients
with uncomplicated obesity with an average BMI of 36. Our
previous study agreed with these findings as we found that obese
subjects with no metabolic complications had similar NK cell
levels and phenotpye to lean controls and it was only metabolically
unhealthy obese subjects which make up 80% of the obese
population, have reduced NK cell levels and altered phenotype. As
uncomplicated obese subjects comprise only 20% of the severely
obese population and have similar peripheral immunity to lean
controls, we focused only on metabolically unhealthy obese
subjects in this study.
Using a novel in vitro assay, we also demonstrate that NK cell
function is significantly compromised by cigarette smoke. Smoke
exposure has previously been shown to increase tumour burden in
mice following tumour challenge and this was due to defects
specifically within the NK cell compartment [8]. In this study, we
Figure 5. Cigarette smoke inhibits upregulation of NK cell activation markers. A. Graph representing expression of perforin marker CD107
and activation marker CD69 on NK cells after stimulation with K562 tumour cells for 4 hours (n=14). Cigarette smoke (equivalent to 20/day)
significantly inhibited the upregulation of both CD107 (*p=0.01) and CD69 (**p=0.006). Adiponectin in the presence of smoke could significantly
restore CD107 expression to normal (*p=0.03) but not CD69 (p=0.3). B. Representive flow cytometry dot plots of one subject illustrating the
inhibition of CD107 and CD69 upregulation in the presence of smoke. Using flow cytometry, CD45
+ lymphocytes were gated and within this gate, NK
cells (CD56
+) were plotted against CD107 or CD69. Cells in the upper right hand quadrant represent the proportion of NK cells expressing CD107 or
CD69. C. Cigarette smoke did not significantly alter intracellular production of IFN-c or IL-10 by NK cells after tumour challenge (n=5, p=0.09, p=0.1
respectively), but when adiponectin was added in addition to smoke, production of IFN-c was significantly increased (**p=0.006).
doi:10.1371/journal.pone.0008660.g005
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and cigarette smoke-induced inhibition of NK function is even
more marked in obese individuals. The effects of CSE on human
NK cells are dramatic with a reduction in cytotoxicity, as well
as perforin and cytokine production. The effects of CSE on NK
function are dose dependent, with similar effects at concen-
trations equivalent to those seen in individuals who smoke 10 or
20/day with more marked effects at concentrations equivalent
to 40/day.
The increased prevalence of diseases associated with cigarette
smoke and their association with smoke induced immune changes
was first recognized in the 1960’s [28]. In murine models, cigarette
smoke acts specifically on the NK cell population of immune cells,
but no mechanism was identified to explain these effects [8]. In the
presence of tumour challenge, CSE inhibited tumour cell killing,
suggesting that CSE impaired NK cell function. We have
demonstrated that although cigarette smoke inhibits NK function,
it is not an indiscriminant toxin, as it did not affect circulating NK
cell survival or tumour death. NK cell levels and tumour viability
were similar whether exposed to CSE or media alone. However,
CSE inhibited up-regulation of CD69, and inhibited the release of
perforin, as seen by surface expression of CD107. Normally NK
cells, upon activation up-regulate CD69 and secrete cytokines and
chemokines that recruit and regulate the subsequent adaptive
immune response [29]. In addition, NK cells directly kill tumours
by release of their cytotoxic granules including perforin, which
perforate and cause apoptosis of the tumour cell. Expression of
NK surface inhibitory receptors CD158a, CD158b and NKB1
were unaltered by CSE. This suggests that cellular signaling events
downstream of these receptors are affected by CSE, resulting in
reduced cytotoxicity.
In this study, we show that adiponectin enhances NK function
in lean subjects. The original view of the adipokines was that their
role was mainly involved in energy homeostasis. However recently
adiponectin and leptin have been implicated in the regulation of
the immune system and receptors for both have been identified on
NK cells [30,31,32]. In addition leptin and adiponectin concen-
trations are determined by the degree of obesity, directly in the
case of leptin and inversely in the case of adiponectin [32,33]. Our
finding that adiponectin increased basal NK cell cytotoxicity in
lean subjects was in contrast to a previous study [32] which
showed that adiponectin inhibited IL-12-enhanced NK cell
cytotoxicity but not basal NK cell cytotoxicity. Some differences
in methodology may account for this difference; we used freshly
isolated human NK cells, in contrast to cultured human NK cell
lines and murine NK cells and employed a flow cytometric-based
cytotoxicity assay as opposed to chromium release assay and the
effects of adiponectin on IL-12-enhanced cytotoxicity was not
measured or appropriate in this study. Our finding that
adiponectin enhanced basal NK cell cytotoxicity in lean patients
and also partially protected smoke-inhibition of NK cell
cytotoxicity fits well with the protective role that has been
proposed for adiponectin in cancer and diseases [34,35,36,37,38]
and in promoting metabolic health [39]. It therefore makes sense
that adiponectin may positively influence NK cell actions.
Moreover, the finding that NK cells from obese subjects do not
respond to adiponectin may have implications for immune
surveillance in the obese individual. Adiponectin is anti-angiogenic
and anti-inflammatory, and inhibits tumour growth in animals.
Inverse associations between adiponectin concentrations and
cancer risk have been reported in human studies [40,41].
Decreased circulating levels of adiponectin have been associated
with several obesity-related malignancies [38,42,43]. Additionally,
our finding that adiponectin enhances NK function in lean but not
in obese subjects suggests that NK cells from obese subjects might
be resistant to the effects of adiponectin.
We demonstrate that adiponectin protects against cigarette
smoke induced suppression of NK cell function. Our results
suggest that this protective effect is mediated through enhancing
basal NK cell cytotoxicity and by restoring NK cell function in the
presence of cigarette smoke. We demonstrate adiponectin
enhanced NK cell activation and release of cytotoxic granules
upon tumour challenge. Adiponectin may block the actions of
smoke on NK cells directly or may enhance NK cell function,
which counterbalances the harmful effects of cigarette smoke.
Further studies are required to determine the mechanisms of
smoke-induced decrease in NK cell functions and the remedial
effects of adiponectin.
This is the first study to demonstrate that obesity compromises
NK function in humans and that cigarette smoke further impairs
the function of NK cells from obese people. Our findings also show
that adiponectin can enhance NK function and protect NK cell
function in obesity from the effects of smoke. This suggests that
adiponectin may have therapeutic potential for reducing the risk of
malignancy or infection in obese subjects and smokers. The lower
levels of adiponectin seen in obesity may compromise the ability of
the NK cell to respond when challenged. Overall this study
confirms that obesity is an immune compromised state and
smoking has additional suppressive effects of NK function. This
may play a role in the increase of cancer and infection seen in this
population [1,16].
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